Angiotensin-1-7 long-acting

Drug Profile

Angiotensin-1-7 long-acting

Alternative Names: Lanthionine-stabilized angiotensin-(1-7) agonistic peptide; Lanthionine-stablised angiotensin-(1-7) agonistic peptide; PanCyte

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lanthio Pharma
  • Developer Tarix Pharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Hormones; Peptide hormones; Peptides
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chemotherapy-induced anaemia; Lung disorders; Neutropenia; Peripheral vascular disorders; Stroke; Thrombocytopenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy-induced-anaemia in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neutropenia(Chemotherapy-induced) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top